Search Results
Aug 11, 2025, 13:30 ET Boehringer Ingelheim Celebrates Next Generation of Biomedical Researchers at 2025 Veterinary Scholars Symposium
artificial intelligence in veterinary research, strategies for the prevention and control of highly pathogenic avian influenza, and the potential of gene editing technologies to address diseases in food animals. Students also had the opportunity to participate in a virtual reality (VR) experience
More news about: Boehringer Ingelheim Animal Health USA Inc.
Aug 11, 2025, 13:01 ET Former Comptroller of the Currency Gene Ludwig Addresses Misleading Headline Economic Statistics in Upcoming Book "The Mismeasurement of America"
@LISEP_org. About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is founder of the Promontory family of companies and Canapi LLC, a financial technology
More news about: Ludwig Institute for Shared Economic Prosperity
Aug 11, 2025, 13:00 ET CHICKEN SALAD CHICK EXPANDS FOOTPRINT IN NORTH CAROLINA WITH NEW BERN GRAND OPENING
LLC. The restaurant is owned and operated by Matt Massengill and Ian, Garrett, and Gene Wickline. Gene is the father of Ian and Garrett, who alongside their friend Matt, will be leading operations of their new Chicken Salad Chick franchise.
More news about: Chicken Salad Chick
Aug 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Aug 11, 2025, 08:45 ET SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Aug 11, 2025, 07:00 ET Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
urothelial cancers and other FGFR3-expressing solid tumorsCompassionate use of opakalim (BHV-7000) in a child with intractable epilepsy due to Kv7 gene mutation (KCNQ2 Developmental and Epileptic Encephalopathy [KCNQ2-DEE]) provides early evidence of potential clinical benefit associated with Biohaven's
More news about: Biohaven Ltd.
Aug 11, 2025, 05:58 ET ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing
Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP Adeno-Associated Virus (AAV) manufacturing services at its 128,000 sq. ft. state-of-the-art
More news about: ProBio Inc.
Aug 08, 2025, 21:40 ET SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ("Duchenne"), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that
More news about: Robbins Geller Rudman & Dowd LLP
Aug 08, 2025, 15:22 ET SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.
Aug 08, 2025, 14:16 ET DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025
CLICK HERE. Rocket Pharmaceuticals, headquartered in Cranbury, New Jersey, specializes in gene therapies for rare and life-threatening diseases. The lawsuit claims the Company failed to disclose major safety-related updates to its RP-A501
More news about: Berger Montague
Aug 08, 2025, 08:45 ET August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Aug 07, 2025, 16:03 ET BioLife Solutions Reports Second Quarter 2025 Financial Results
Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and six months ended June 30, 2025.
More news about: BioLife Solutions, Inc.
Aug 07, 2025, 12:34 ET LabConnect Partners with Kits4Life to Reduce Kit Waste and Advance Sustainable Clinical Trials
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Aug 07, 2025, 12:19 ET LabConnect Partners with Kits4Life to Reduce Kit Waste and Advance Sustainable Clinical Trials
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Aug 07, 2025, 10:15 ET Brain Computer Interface Market to Soar from USD 1.6 Billion in 2024 to USD 6.3 Billion by 2033, at 20.5% CAGR - Market Research Intellect
Cloud-Based Platforms, Data Analytics Solutions, Telehealth Solutions, Patient Management Systems) and Other Emerging Therapies (Stem Cell Therapy, Gene Therapy, Biosensors, Nanotechnology-Based Solutions, Non-Invasive Glucose Monitoring) and geographical regions About Us: Market Research
More news about: Market Research Intellect
Aug 07, 2025, 10:04 ET Kedrion receives FDA Orphan Drug Designation for investigational plasma-derived treatment for Congenital Aceruloplasminemia
About Congenital Aceruloplasminemia Aceruloplasminemia is an autosomal recessive disorder caused by mutations in the CP gene, leading to a deficiency or absence of ceruloplasmin, a protein essential for iron transport. The condition results in iron accumulation
More news about: Kedrion Biopharma
Aug 07, 2025, 08:31 ET Warren Nicholson Appointed to the Alabama Quantum Evaluation Task Force by Governor Kay Ivey
nfina.com Contact: Gene [email protected]
More news about: Nfina Technologies
Aug 07, 2025, 08:00 ET Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
participants with Duchenne who have been previously treated with gene therapy. FOX participants are on average over 10 years old and four years out from receiving gene therapy. Despite the lack of extensive natural history in Duchenne gene therapy treated boys, initial results from the FOX study support
More news about: Edgewise Therapeutics
Aug 07, 2025, 08:00 ET K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration with Bayer for Supply of Darolutamide
KTX-2001, a selective, oral inhibitor of NSD2 (nuclear receptor-binding SET domain protein 2), a histone methyltransferase and oncogene that activates gene expression in some cancers.
More news about: K36 Therapeutics
Aug 07, 2025, 07:05 ET REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Aug 07, 2025, 07:00 ET REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Aug 07, 2025, 07:00 ET Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Phase 3 study of TPIP in patients with PAH in early 2026.Gene Therapy Insmed dosed the first patient in the Phase 1 ASCEND clinical study of INS1201, an intrathecally-delivered gene therapy for patients with Duchenne muscular dystrophy (DMD), in July
More news about: Insmed Incorporated
Aug 07, 2025, 06:00 ET Ecovyst Reports Second Quarter 2025 Results
https://investor.ecovyst.com/events-presentations. Investor Contact: Gene Shiels(484) [email protected]
More news about: Ecovyst Inc.
Aug 07, 2025, 02:35 ET US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
MYC-Driven Lymphomas – 30% of Cancers Involve MYC Mutation MYC is a critical oncogene, with approximately 28% of cancer patients exhibiting gene amplification or mutation, including in lung, breast, liver cancers, and lymphomas. The MYC protein drives cell proliferation, angiogenesis, and apoptosis
More news about: Senhwa Biosciences, Inc.
Aug 06, 2025, 17:31 ET CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight
SRPK, which also participate in splicing regulation. Additionally, as these agents target fundamental RNA processes, safety concerns related to broad gene expression changes need to be carefully assessed in clinical trials. Regulatory guidance for RNA-targeting therapies is still evolving, potentially
More news about: DelveInsight Business Research, LLP